Chemours Co — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Chemours reported Q2 2026 net sales of $1.59B (down $24M YoY from $1.62B) and Adjusted EBITDA of $247M (down $13M YoY from $260M). Free cash flow improved 128% to $114M with 46% conversion. Net leverage declined to 4.4x from prior levels; company repaid €230M debt in Q2 and achieved $287M net proceeds from Kuan Yin site sale. Three TiO2 price increases implemented; APM Performance Solutions grew 8% YoY; TSS Opteon refrigerant sales driven by regulatory transition. Company targets below 3.0x leverage long-term, $250M cost reductions by 2027, and 5% sales CAGR 2024–2027.
Why this rating
Modest sales/EBITDA decline offset by improved FCF and deleveraging. Asset sale proceeds and debt reduction progress toward stated goals. No material business disruption; routine operational execution on Pathway to Thrive strategy.
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.